drugset / Trial / NCT00690079

Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386

NCT00690079

Phase 1 Completed 69 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being performed in order to learn more about the safety and tolerability of AZD1386. AZD1386 is primary intended for treatment of chronic pain.

Timeline

Start
2008-02
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1386 Small molecule Oral

Indications